Streetbeat News

Analyst Ratings

UTHR

United Therapeutics Inc. (NASDAQ:UTHR) stock is currently priced at $350.07, showing a slight decrease of 0.68% in the current session. Over the past year, the stock has increased by 49.39%. The company's P/E ratio is 16.2, lower than the Biotechnology industry average of 61.21, suggesting potential undervaluation or lower growth expectations.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 8:46 pm

APAM

Analysts have recently shared mixed ratings on Artisan Partners Asset (NYSE:APAM), with a notable decrease in the average 12-month price target by 2.64%. The company's financials show strong revenue growth and return on equity, but challenges in net margin and market capitalization.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 8:02 pm

KKR

In the past three months, 16 analysts have provided ratings for KKR, with a majority being bullish. The average 12-month price target for KKR has increased by 9.74% to $138.44. Analysts have adjusted their ratings and price targets, reflecting positive sentiment towards KKR's market performance. Despite strong revenue growth, KKR faces challenges with profitability and financial risk due to high debt levels.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 8:01 pm

LRCX

In the past three months, 13 analysts have provided ratings for Lam Research (NASDAQ:LRCX), with a mix of bullish and bearish perspectives. The average 12-month price target has decreased by 6.44%, indicating a negative shift in sentiment. Analysts have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Lam Research, a leading semiconductor wafer fabrication equipment manufacturer, has shown strong financial performance with a 20.71% revenue growth rate and high net margins, but faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 8:01 pm

CHPT

Analysts have recently updated their ratings and price targets for ChargePoint Holdings (NYSE:CHPT), with a general trend of lowering expectations. The average 12-month price target has decreased by 24.31% to $2.46. Analysts have expressed mixed sentiments, with some maintaining a 'Buy' rating while others have downgraded to 'Sell' or 'Hold'. ChargePoint faces challenges with declining revenue growth and below-average financial metrics, despite having a strong net margin.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 8:01 pm

WOLF

Analysts have recently evaluated Wolfspeed (NYSE:WOLF), with a range of opinions from bullish to bearish. The average 12-month price target has declined by 38.35%, with a current average of $16.3. Analysts have lowered their ratings and price targets, reflecting challenges in Wolfspeed's financial performance, including revenue decline, low net margin, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 8:00 pm

MRK

Merck & Co (NYSE:MRK) has been the subject of recent analyst reviews, with opinions ranging from bullish to bearish. The average 12-month price target has decreased by 2.29% to $144.12. Analysts have adjusted their ratings and price targets, reflecting changing market dynamics. Merck's financial performance shows strong profitability and effective cost control, with a net margin of 33.86% and a return on equity of 13.0%.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 8:00 pm

ENOV

JMP Securities initiated coverage on Enovis Corporation (NYSE:ENOV), highlighting its M&A strategy as a core growth driver. Enovis has made around 20 acquisitions in the past 4.5 years, including the significant acquisition of LimaCorporate. The integration of LimaCorporate is progressing well, with revenues exceeding expectations. Despite a 25% YTD decline in stock price, the analyst sees Enovis as undervalued and deserving of a higher P/E multiple, initiating a Market Outperform rating with a $62 price target.

Portfolio Pulse from Vandana Singh

October 03, 2024 | 7:39 pm

FANG

Diamondback Energy (NASDAQ:FANG) has seen significant options activity, with a mix of bullish and bearish trades. The options trades suggest a price target range of $160 to $270. The stock is currently trading at $188.5, up 3.98%, and may be approaching overbought territory. Analysts have mixed ratings, with price targets ranging from $182 to $237.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 7:35 pm

FANG

Diamondback Energy's stock is experiencing an uptick following Benchmark's decision to maintain a Buy rating and increase the price target from $154 to $195.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 7:28 pm